R. Jude Samulski

Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease

Retrieved on: 
Tuesday, June 8, 2021

In parallel a gene therapy investigational program also targeted at providing advanced therapies for Parkinsons disease is driven forward by Bayers wholly-owned clinical-stage adeno-associated virus (AAV) gene therapy company Asklepios BioPharmaceutical Inc. (AskBio).

Key Points: 
  • In parallel a gene therapy investigational program also targeted at providing advanced therapies for Parkinsons disease is driven forward by Bayers wholly-owned clinical-stage adeno-associated virus (AAV) gene therapy company Asklepios BioPharmaceutical Inc. (AskBio).
  • The potential of BlueRock and AskBios clinical candidates to treat Parkinsons disease and truly help patients with their high unmet medical need could be immense, said Wolfram Carius, Head of Cell and Gene Therapy at Bayer.
  • Parkinsons disease is the most common neurodegenerative movement disorder, impacting more than 10 million people worldwide.
  • By targeting the disease at its root cause, cell and gene therapies aim to go beyond symptomatic treatments.

LEXEO Therapeutics Strengthens Management Team with Key Appointments to Accelerate Development of Clinical-Stage Pipeline

Retrieved on: 
Tuesday, April 6, 2021

LEXEO Therapeutics was purpose-built as a fully integrated gene therapy company to advance a truly unique clinical-stage pipeline currently focused on monogenic rare cardiac and CNS diseases, said R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics.

Key Points: 
  • LEXEO Therapeutics was purpose-built as a fully integrated gene therapy company to advance a truly unique clinical-stage pipeline currently focused on monogenic rare cardiac and CNS diseases, said R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics.
  • From 2008 to 2016, he was a product development leader in Pfizers manufacturing organization, leading late-stage development and commercialization of large molecule products.
  • Prior to joining Pfizer, he held positions in process development at Avecia Biotechnology, a leading contract manufacturer of oligonucleotide therapeutics.
  • LEXEO Therapeutics pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicines Department of Genetic Medicine.

Freeline to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 30, 2021

20th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.

Key Points: 
  • 20th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.
  • Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.
  • The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.
  • The Companys integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization.

Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy

Retrieved on: 
Monday, October 26, 2020

Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas.

Key Points: 
  • Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas.
  • The addition of AskBio to Bayers emerging cell and gene therapy (CGT) business strengthens Bayers commitment to the field.
  • Besides multiple clinical-stage assets for indications with high unmet need, the acquisition includes a state-of-the-art gene therapy technology platform as well as existing gene therapy manufacturing platform.
  • AskBios gene therapy platform includes an industry-leading cell line manufacturing process and an extensive AAV capsid and promoter library.

AskBio CSO Jude Samulski Receives 2020 Life Sciences Award from the Triangle Business Journal

Retrieved on: 
Monday, August 24, 2020

RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its president and chief scientific officer, Jude Samulski, PhD, has been honored as one of the Triangle Business Journals (TBJ) 2020 Life Sciences Award winners.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that its president and chief scientific officer, Jude Samulski, PhD, has been honored as one of the Triangle Business Journals (TBJ) 2020 Life Sciences Award winners.
  • The award recognizes individuals and research organizations at the forefront of innovation in the growing Triangle-area life sciences industry, representing biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics.
  • Its an honor to be recognized as part of this esteemed group that is driving transformation and growth in our local life sciences industry, said Samulski.
  • This is the second recent accolade for Samulski, who was named one of PharmaVOICE Magazines Most Inspiring Leaders in Life Sciences earlier this month.

AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System

Retrieved on: 
Tuesday, June 23, 2020

Working at the intersection of gene editing and AAV, my team and I found that this regulated gene editing system used in vivo is more precise and has higher specificity and reliability for its target.

Key Points: 
  • Working at the intersection of gene editing and AAV, my team and I found that this regulated gene editing system used in vivo is more precise and has higher specificity and reliability for its target.
  • Samulskis regulated gene editing system uses an oligonucleotide small molecule that can regulate the function of any gene by selectively turning on or off the expression of the gene.
  • A pioneer in gene therapy, Samulski holds the first U.S. patent involving non-AAV genes inserted into AAV, and he is the lead inventor on more than 300 patents in the field of AAV vectors and gene therapy.
  • AskBios gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid and promoter library.

SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer

Retrieved on: 
Monday, June 1, 2020

"We are thrilled to add Steven's expertise to our leadership team," said Tom Anderson, CEO and Director of SwanBio Therapeutics.

Key Points: 
  • "We are thrilled to add Steven's expertise to our leadership team," said Tom Anderson, CEO and Director of SwanBio Therapeutics.
  • "SwanBio Therapeutics is taking a unique and highly strategic approach to building their pipeline of adeno-associated virus-based gene therapies," said Dr. Zelenkofske.
  • SwanBio Therapeutics is a privately held company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of neurological diseases with significant unmet medical need.
  • SwanBio Therapeutics is based in Bala Cynwyd, Pennsylvania and has operations in Philadelphia, Pennsylvania and Cambridge, Massachusetts.

Don Haut, PhD, Joins AskBio as Chief Business Officer

Retrieved on: 
Tuesday, April 7, 2020

RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Don Haut, PhD, has been appointed its Chief Business Officer to oversee business development strategy and execution.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Don Haut, PhD, has been appointed its Chief Business Officer to oversee business development strategy and execution.
  • Don has a wealth of strategy and business development experience in the biotechnology and medical technology fields.
  • He previously served as Chief Business Officer at Sherlock Biosciences and Histogenics, Inc.
  • Prior to that, he was Vice President for New Business and Vice President for American Sales Operations at The Medicines Company.

StrideBio Appoints Maritza Mcintyre, Ph.D., As Chief Development Officer

Retrieved on: 
Thursday, April 2, 2020

RESEARCH TRIANGLE PARK, N.C., April 2, 2020 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 2, 2020 /PRNewswire/ -- StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer.
  • Dr. McIntyre is a virologist with over 20 years of experience in the development, evaluation and regulation of gene therapy, biological and small molecule products.
  • "We are delighted to have Dr. McIntyre join the StrideBio team as Chief Development Officer," said Sapan Shah, Ph.D., Chief Executive Officer.
  • I look forward to leading StrideBio's programs through this next phase of translational development and into the clinic."

Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy

Retrieved on: 
Thursday, March 12, 2020

RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Kelly, PhD, as President of Manufacturing.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Kelly, PhD, as President of Manufacturing.
  • He will oversee all manufacturing functions at AskBio and its Viralgen affiliate for the production of clinical- and commercial-scale AAV vectors.
  • To meet the growing demand for AAV gene therapies, the company is investing in manufacturing innovation, talent and capacity that will allow it to effectively and efficiently serve patient populations.
  • AskBios gene therapy platform includes an industry-leading proprietary cell line manufacturing process called Pro10 and an extensive AAV capsid and promoter library.